Selective inhibitors of DYRK1A have been extensively explored and are considered potential candidates for treating multiple diseases, including Down’s syndrome, Alzheimer’s disease, Parkinson’s disease and cancer [38]. This evidence concerns the gene DYRK1A and early-onset autosomal dominant Alzheimer disease.